09315567 is referenced by 1 patents and cites 68 patents.

The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon-based agents that comprise interferon-α, interferon-β, interferon-λ1, interferon-λ2 or interferon-λ3.

Title
T-cell redirecting bispecific antibodies for treatment of disease
Application Number
13/966450
Publication Number
9315567 (B2)
Application Date
August 14, 2013
Publication Date
April 19, 2016
Inventor
Diane Rossi
Woodland Park
NJ, US
Edmund A Rossi
Woodland Park
NJ, US
David M Goldenberg
Mendham
NJ, US
Chien Hsing Chang
Downingtown
PA, US
Agent
Richard A Nakashima
Assignee
IBC Pharmaceuticals
NJ, US
IPC
A61K 39/00
C07K 16/32
C07K 16/40
A61K 38/19
A61K 45/06
A61K 47/42
C07K 16/18
C07K 16/44
A61K 39/395
A61K 38/21
C07K 16/30
C07K 16/28
C07K 16/46
View Original Source